CZC-25146

Cat. No.: IBDI-431436

CZC-25146 is a potent and orally active LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases.

Product Details

Target	LRRK2
Molecular Weight	488.54
Appearance	Solid
SMILES	CS(=O)(NC1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCOCC4)C=C3OC)=NC=C2F)=O
Purity	98.85%

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Powder: -20°C/3 years; 4°C/2 years In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.